Here’s Why Visa Shares Are Trading Higher

Visa Inc (NYSE: V) shares are trading higher by 2.54% to $230.37 Friday after the company reported better-than-expected first-quarter results.

Visa Inc (NYSE:V) shares are trading higher by 2.54% to $230.37 Friday after the company reported better-than-expected first-quarter results. Multiple analysts maintained bullish ratings on the stock and raised their price targets on the stock following the report.

What Happened?

Visa reported quarterly earnings of $2.18 per share which beat the analyst consensus estimate of $2.01. The company also reported quarterly sales of $7.90 billion which beat the analyst consensus estimate of $7.70 billion by 2.6%. This is a 12% increase over sales of $7.06 billion in the same period last year.

Meanwhile, payments volume for the three months ended September 30, 2022, on which fiscal first quarter service revenues are recognized, increased 10% over the prior year on a constant-dollar basis.

See Also: Why Bitcoin- And Ethereum-Related Stock Silvergate Capital Is Nosediving

Visa also says payments volume for the three months ended December 31, 2022, increased 7% over the prior year on a constant-dollar basis.

Among analyst rating updates for the stock on Friday are the following:

  • Credit Suisse analyst Moshe Orenbuch maintained with an Outperform and raised the price target from $245 to $250.
  • Raymond James analyst John Davis maintained with an Outperform and raised the price target from $261 to $281.
  • Wells Fargo analyst Donald Fandetti maintained with an Overweight and raised the price target from $250 to $265.

According to data from Benzinga Pro, Visa Inc has a 52-week high of $250.58 and a 52-week low of $174.60.

Total
0
Shares
Related Posts
Read More

Martin Midstream Partners And 2 Other Stocks Under $5 Insiders Are Buying

The Dow Jones closed higher on Monday, also recording gains for the month of July. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

EFSH

Read More

EXCLUSIVE: Cell Therapy Player Lineage Cell Therapeutics Starts Development Activities Under Licensing Pact With Eterna Therapeutics

Lineage Cell Therapeutics Inc (NYSE: LCTX) has initiated certain development activities to generate a novel hypoimmune induced pluripotent stem cell (iPSC) line under the company’s exclusive option and license agreement with Eterna Therapeutics Inc (NASDAQ:

ERNA